HC Wainwright & Co. Reiterates Buy on Beam Therapeutics, Maintains $80 Price Target

Benzinga · 03/10 17:15
HC Wainwright & Co. analyst Patrick Trucchio reiterates Beam Therapeutics (NASDAQ:BEAM) with a Buy and maintains $80 price target.